TECLens conducts first clinical trial for non-surgical vision correction technology

USA—TECLens has treated its first patient in a groundbreaking clinical trial that could transform how doctors correct vision problems.

The company’s quantitative corneal crosslinking (qCXL) technology offers a non-invasive alternative to traditional eye surgery, eliminating the need to cut or remove corneal tissue.

The innovative approach strengthens the cornea through targeted molecular bonding rather than tissue removal.

This represents a significant departure from conventional surgical methods that have dominated refractive vision correction for decades.

How the CXLens system works

The proprietary CXLens system delivers patterned ultraviolet light to reshape the cornea while keeping the epithelium—the eye’s protective outer layer—completely intact.

The technology creates specific molecular bonds in targeted areas of the cornea, which strengthens the tissue and reshapes it to improve vision.

A customized treatment planning engine guides each procedure, while real-time ultrasound monitoring ensures precision throughout the process.

This combination allows physicians to perform the treatment in their office rather than requiring an operating room setting.

The entire procedure maintains the epithelium-on approach, meaning patients avoid the risks and recovery time associated with surgical interventions.

This in-office treatment model provides new flexibility for both patients and physicians who previously had limited options for vision correction.

Targeting a global health challenge

The clinical trial focuses primarily on patients with refractive errors, particularly those suffering from presbyopia.

This age-related condition affects approximately two billion people worldwide, making it one of the most common vision problems globally.

Presbyopia typically develops as people age, reducing their ability to focus on close objects.

Current treatment options remain limited, making TECLens’s approach particularly significant for this massive patient population.

Industry impact and future potential

Thomas Dunlap, CEO of TECLens, emphasized the transformative nature of this milestone.

The company aims to create an entirely new category in ophthalmology by moving vision correction from the operating room to the examination room.

The qCXL technology positions itself as a potential first-line treatment for both refractive errors and presbyopia, expanding treatment options for millions of patients who might otherwise require surgery.

By eliminating surgical intervention, the technology could make vision correction more accessible and less intimidating for patients hesitant about traditional procedures.

Company background and support

TECLens specializes in developing non-invasive quantitative corneal crosslinking technology specifically for vision correction applications.

The CXLens system employs patterned UV light combined with continuous biomechanical control to reshape the cornea safely and effectively.

The company has attracted substantial backing from prominent investors, including Johnson & Johnson Innovation – JJDC, Rimonci Capital, Sunmed Capital, and Yonjin Venture.

This financial support underscores the industry’s confidence in the technology’s potential to reshape the vision correction landscape.